4.5 Article

Optimization of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase Based on Group Efficiency Analysis

期刊

CHEMMEDCHEM
卷 11, 期 1, 页码 38-42

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500414

关键词

drug design; fragment-based screening; group efficiency; Mycobacterium tuberculosis; pantothenate synthetase

资金

  1. Bill & Melinda Gates Foundation
  2. UK Biotechnology and Biological Sciences Research Council [BB/D006104/1]
  3. Fundacao para a Ciencia e Tecnologia (FCT), Portugal
  4. Homerton College, Cambridge
  5. Agency for Science, Technology and Research (A*STAR), Singapore
  6. BBSRC [BB/D006104/1] Funding Source: UKRI
  7. EPSRC [EP/K039520/1] Funding Source: UKRI
  8. Biotechnology and Biological Sciences Research Council [BB/D006104/1] Funding Source: researchfish
  9. Engineering and Physical Sciences Research Council [EP/K039520/1] Funding Source: researchfish

向作者/读者索取更多资源

Ligand efficiency has proven to be a valuable concept for optimization of leads in the early stages of drug design. Taking this one step further, group efficiency (GE) evaluates the binding efficiency of each appendage of a molecule, further fine-tuning the drug design process. Here, GE analysis is used to systematically improve the potency of inhibitors of Mycobacterium tuberculosis pantothenate synthetase, an important target in tuberculosis therapy. Binding efficiencies were found to be distributed unevenly within a lead molecule derived using a fragment-based approach. Substitution of the less efficient parts of the molecule allowed systematic development of more potent compounds. This method of dissecting and analyzing different groups within a molecule offers a rational and general way of carrying out lead optimization, with potential broad application within drug discovery.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据